Today: 20 May 2026
Thermo Fisher (TMO) stock rises as Goldman lifts target ahead of Jan. 29 earnings
21 January 2026
1 min read

Thermo Fisher (TMO) stock rises as Goldman lifts target ahead of Jan. 29 earnings

New York, January 21, 2026, 12:38 EST — During the regular session

  • Thermo Fisher shares surged beyond a modest market bounce as investors gear up for next week’s earnings.
  • A new SEC filing and a Goldman Sachs boost to the price target kept the spotlight on the stock.
  • Investors are eyeing the company’s earnings release and conference call set for January 29 as the next key catalyst.

Thermo Fisher Scientific shares climbed roughly 1.6% to $628.63 by midday Wednesday, beating the wider market gains.

This shift is crucial as investors brace for the company’s quarterly report next week, where management’s comments on lab demand and pharma services usually steer the stock’s near-term trajectory.

This week, markets remain jittery, and defensive healthcare stocks are drawing interest despite the volatility. Thermo Fisher stands out, offering a mix of growth potential and stability.

On Tuesday, Goldman Sachs boosted its price target for Thermo Fisher to $710 from $685, maintaining a “buy” rating, MarketScreener reported. MarketScreener

In a separate filing Wednesday, the New York Stock Exchange alerted the SEC that Thermo Fisher’s 3.200% senior notes maturing in 2026 are being delisted or deregistered. This action concerns the debt instrument only, not Thermo Fisher’s common shares.

Peers showed strength too. Danaher climbed around 1.8%, while Agilent rose about 1.4%, indicating the boost wasn’t confined to just one name.

Waltham, Massachusetts-based Thermo Fisher sells lab equipment and offers services to drugmakers, including manufacturing support via its pharma services unit.

Speaking at last week’s J.P. Morgan Healthcare Conference, CEO Marc Casper highlighted a surge in customers pushing to shift production back to the U.S. “There’s a very big focus on reshoring more production and activity to the U.S.,” he noted. Reuters

But bulls should beware: if the company’s guidance signals caution on biotech and pharma spending, or if order trends vary significantly across regions, the stock’s pre-earnings rally could quickly lose steam.

Thermo Fisher is set to release earnings on January 29, ahead of the market open, followed by a conference call at 8:30 a.m. ET. Investors will focus on demand trends for lab tools, progress in pharma services, and insights into customer spending plans for 2026.

Stock Market Today

  • Williams-Sonoma Gains 1.58% as Market Declines, Eyes Upcoming Earnings
    May 19, 2026, 7:31 PM EDT. Williams-Sonoma (WSM) shares rose 1.58% to $171.83, outperforming the S&P 500's 0.67% drop. The stock had declined 16.27% over the past month, lagging the sector's 0.69% loss but behind the S&P 500's 4% gain. Investors await WSM's upcoming earnings report, expected to show $1.80 per share in EPS, down 2.7% year-over-year, with revenue projected to rise 4.25% to $1.8 billion. The company's full-year estimates anticipate 4.75% EPS growth and 4.39% revenue growth. Analyst estimate revisions have nudged EPS projections higher by 0.58% in 30 days, with WSM holding a Zacks Rank #3 (Hold). Valuation indicators show a Forward P/E of 18.27, slightly below industry average, while the PEG ratio of 2.12 exceeds the Retail - Home Furnishings sector average of 1.63.

Latest articles

James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Red Robin Shares Rise After Earnings Beat

Red Robin Shares Rise After Earnings Beat

20 May 2026
Red Robin shares surged 15.6% after hours to $4.45 Tuesday, following first-quarter revenue of $378.3 million that beat Wall Street estimates despite a 0.6% drop in comparable sales and a 1.6% decline in guest traffic. Net loss was $2.2 million, or 12 cents per share. The company reaffirmed its 2026 outlook and said refranchising talks are in final stages.
MARA stock jumps 6% as bitcoin miners rebound and CEO share-sale notice hits the tape
Previous Story

MARA stock jumps 6% as bitcoin miners rebound and CEO share-sale notice hits the tape

ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update
Next Story

ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

Go toTop